Aptus Pharma IPO
UpcomingAlready have an account? Apply now
Schedule of Aptus Pharma
| Issue open date | 23 Sep 2025 |
| Issue close date | 25 Sep 2025 |
| UPI mandate deadline | 25 Sep 2025 (5 PM) |
| Allotment finalization | 26 Sep 2025 |
| Refund initiation | 29 Sep 2025 |
| Share credit | 29 Sep 2025 |
| Listing date | 30 Sep 2025 |
| Mandate end date | 10 Oct 2025 |
| Lock-in end date for anchor investors (50%) | 26 Oct 2025 |
| Lock-in end date for anchor investors (remaining) | 25 Dec 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Aptus Pharma
Aptus Pharma is a Gujarat-based pharmaceutical company incorporated in 2010, engaged in marketing and distribution of finished pharmaceutical formulations. The company operates through a contract manufacturing model without owning manufacturing facilities, partnering with seven manufacturing units. Aptus offers a diverse range of pharmaceutical products across therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, and wellness products. Products are available in various dosage forms including tablets, capsules, syrups, injections, ointments, and drops.
Financials of Aptus Pharma
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹ 13.02 crores |
| Fresh Issue | ₹ 13.02 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Capital expenditure | 1.63 (12.5%) |
| Working capital requirements | 8.00 (61.5%) |
| General Corporate Purposes and miscellaneous | 3.39 (26%) |
Strengths
- Established presence in pharmaceutical marketing and distribution since 2010
- Diverse product portfolio across multiple therapeutic categories and dosage forms
- Partnership network with seven manufacturing units providing operational flexibility
- Experienced promoter group with pharmaceutical industry expertise
Risks
- Complete dependence on contract manufacturers creating supply chain vulnerabilities
- Lack of manufacturing facilities limiting control over production quality and costs
- Regulatory compliance risks across multiple therapeutic categories and formulations
- Dependence on key manufacturing partners for business continuity and product quality
Allotment Status for Aptus Pharma
To check your allotment status – click here.